Novartis Aktie
93,56
EUR
-0,45
EUR
-0,48
%
87,04
CHF
-1,00
CHF
-1,14
%
Kursziele der Novartis-Aktie in CHF
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Deutsche Bank AG | 100,00 CHF | +14,89% | 17.12.2024 | |
| Jefferies & Company Inc. | - | - | 10.12.2024 | |
| JP Morgan Chase & Co. | 95,00 CHF | +9,15% | 03.12.2024 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 86,00 CHF | -1,19% | 25.11.2024 | |
| Goldman Sachs Group Inc. | 100,00 CHF | +14,89% | 22.11.2024 | |
| Barclays Capital | 85,00 CHF | -2,34% | 21.11.2024 | |
| UBS AG | 111,00 CHF | +27,53% | 21.11.2024 | |
| Bernstein Research | 115,00 CHF | +32,12% | 30.10.2024 | |
| DZ BANK | - | - | 19.07.2024 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 5 | 4 | 0 | 138,26 GBP | - |
| Bayer | 1 | 9 | 0 | 27,22 EUR | +43,44% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | +17,12% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 6 | 1 | 17,14 GBP | +29,65% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 186,71 EUR | - |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 98,86 CHF | +13,58% |
| Pfizer Inc. | 3 | 3 | 0 | 31,20 USD | +21,31% |
| Roche AG (Genussschein) | 2 | 4 | 3 | 274,29 CHF | - |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 5 | 2 | 1 | 109,86 EUR | - |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |